Source BioScience Acquires CCL
In April 2025, Source BioScience UK Ltd, a leading provider of genomic services and histopathology diagnostics, acquired Cambridge Clinical Laboratories (CCL).
The acquisition complements Source BioScience’s established capabilities in genomics and multi-omics, and expands its existing clinical offering, which includes molecular diagnostics, digital pathology and clinical trial support, to provide a complete laboratory service portfolio. By offering comprehensive, end-to-end testing solutions, researchers can confidently progress candidates through R&D, to preclinical and clinical stages with one specialist outsourcing partner – minimising resource requirements and data bias across the entire development process, with the option for additional support in clinical research and diagnostics.
Our Expertise
PERSONALISED HEALTHCARE
CCL is proud to provide healthcare professionals with UKAS accredited testing based in the heart of scientific development, Cambridge, UK.
Our experience is coupled with a rapidly growing portfolio of molecular and virology diagnostics, next generation sequencing, pharmacogenetic and patient profiling tests, all of which employ cutting-edge technology.
Quality service
Being a private and independent laboratory enables us to offer true value to our partners. We can respond to the ever-changing needs of the healthcare diagnostic market in a rapid and effective manner. This directly benefits the clinicians and healthcare providers we work with as they diagnose, treat and monitor their patients.
Our Promise
